CDPPB

CDPPB is a selective, orally active mGluR5 allosteric modulator. CDPPB increases AKT and ERK1/2 activation and augments the BDNF mRNA. CDPPB inhibits caspase-3 activation and mitochondrial dysfunction. CDPPB improves cognitive impairment, depression, and Huntington's disease[1][2][3][4][5][6][7][8][9].

Product Specifications

CAS Number

[781652-57-1]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Akt; Caspase; ERK; mGluR; Mitochondrial Metabolism

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Neuronal Signaling; PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/cdppb.html

Purity

98.01

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC(C2=CC=CC=C2)=NN1C3=CC=CC=C3)C4=CC=CC(C#N)=C4

Molecular Formula

C23H16N4O

Molecular Weight

364.40

Precautions

H302, H315, H319, H335

References & Citations

[1]Kinney GG, et, al. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther. 2005 Apr; 313 (1) :199-206.|[2]Guan DF, et al. The mGluR5 positive allosteric modulator CDPPB inhibits SO₂-induced protein radical formation and mitochondrial dysfunction through activation of Akt in mouse hippocampal HT22 cells. Cell Mol Neurobiol. 2015 May;35 (4) :573-83. |[3]Chen T, et al. Protective effects of mGluR5 positive modulators against traumatic neuronal injury through PKC-dependent activation of MEK/ERK pathway. Neurochem Res. 2012 May;37 (5) :983-90.|[4]Horio M, et al. Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on phencyclidine-induced cognitive deficits in mice. Fundam Clin Pharmacol. 2013 Oct;27 (5) :483-8.|[5]Płoska A, et al. Neurochemical changes underlying cognitive impairment in olfactory bulbectomized rats and the impact of the mGlu5-positive allosteric modulator CDPPB. Brain Res. 2021 Oct 1;1768:147577.|[6]Doria JG, et al. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease. Neurobiol Dis. 2015 Jan;73:163-73. |[7]Zhang L, et al. Post-stress Social Interaction and 3-Cyano-N- (1,3-Diphenyl-1H-Pyrazol-5-yl) Benzamide Treatment Attenuate Depressive-like Behavior Induced by Repeated Social Defeat Stress. Neuroscience. 2024 Feb 6;538:11-21.|[8]Miller-Rhodes P, et al. Sex-specific behavioral impairments produced by neonatal exposure to MK-801 are partially reversed by adolescent CDPPB treatment. Neurotoxicology and Teratology, 2022, 89: 107053.|[9]Bellozi PMQ, et al. A positive allosteric modulator of mGluR5 promotes neuroprotective effects in mouse models of Alzheimer's disease. Neuropharmacology. 2019 Dec 1;160:107785.